Medication-info.com Search Menu

Adzynma (Apadamtase alfa): Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx) Boxed warning
Strength:
500 IU/IU, 1500 IU/IU
Active ingredient:

Patient information: uses, side effects, how to take - Adzynma

What is ADZYNMA?

ADZYNMA is a prescription medicine used to prevent or treat blood clots in patients with congenital thrombotic thrombocytopenic purpura (cTTP). This medicine replaces low amounts of the enzyme (ADAMTS13) in the body.

Who should not take ADZYNMA?

Do not take ADZYNMA if you have had a life-threatening allergic reaction to ADZYNMA, or any of the ingredients in ADZYNMA. See the end of this Patient Information for a complete list of ingredients in ADZYNMA.

What is the most important information I should know about ADZYNMA and hereditary ADAMTS13 deficiency (cTTP)?

Your body can form inhibitors to ADAMTS13. An inhibitor is part of the body’s normal defense system. If you form inhibitors, they may stop ADZYNMA from working properly which could lead to serious complications including death. Consult with your healthcare provider to make sure you are carefully monitored with blood tests for the development of inhibitors to ADAMTS13.

Before you take ADZYNMA, tell your healthcare provider about all of your medical conditions, including if you:

  • have any allergies, including allergies to hamsters.
  • are pregnant or plan to become pregnant. It is not known if ADZYNMA will harm your unborn baby. Tell your healthcare provider right away if you become pregnant while receiving ADZYNMA.

  • are breastfeeding or plan to breastfeed. It is not known if ADZYNMA passes into breast milk. Talk to your healthcare provider about the best way to feed your baby if you take ADZYNMA.

Tell your healthcare provider about all the medicines you take, including prescription medicines and over-the-counter medicines, vitamins, and herbal supplements.

How is ADZYNMA given?

ADZYNMA will be slowly injected into your vein (intravenous injection).

What are the possible side effects of ADZYNMA?

You can have an allergic reaction to ADZYNMA.

Call your healthcare provider right away and stop treatment if you get a rash or hives, itching, tightness of the throat, chest pain or tightness, difficulty breathing, lightheadedness, dizziness, nausea, or fainting.

The most common side effects that have been reported with ADZYNMA include: headache, diarrhea, migraine, abdominal pain, nausea, upper respiratory tract infection, dizziness, and vomiting.

Tell your healthcare provider about any side effect that bothers you or does not go away.

These are not all of the possible side effects of ADZYNMA. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of ADZYNMA

Medicines are sometimes prescribed for purposes other than those listed here. Do not use ADZYNMA for a condition for which it is not prescribed. Do not give ADZYNMA to other people, even if they have the same symptoms you have. It may harm them.

What are the ingredients in ADZYNMA?

Active ingredient: recombinant ADAMTS13.

Inactive ingredients: sodium chloride, calcium chloride dihydrate, L-histidine, mannitol, sucrose, and polysorbate 80.

Resources at Takeda available to the patients:

For more product information on ADZYNMA, please visit www.ADZYNMA.com or call 1-877-TAKEDA-7 (1-877-825-3327).

For information on additional Takeda patient resources, please visit www.ADZYNMA.com.

Manufactured by:

Takeda Pharmaceuticals U.S.A., Inc.

Cambridge, MA 02142

U.S. License No. 1898

ADZYNMA and are trademarks of Takeda Pharmaceuticals International AG.

BAXJECT® is a registered trademark of Baxalta Incorporated.

TAKEDA® and are registered trademarks of Takeda Pharmaceutical Company Limited.

Patented: see https://www.takeda.com/en-us/patents

©2026 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved.

ADZ379 R4

INSTRUCTIONS FOR USE

ADZYNMA

(ad-zin-muh)

(ADAMTS13, recombinant-krhn)

Lyophilized Powder for Injection, for Intravenous Use

Single-Dose Vial

The following information is intended for medical or healthcare professionals only.

This Instructions for Use contains information on how to reconstitute and infuse ADZYNMA. This Instructions for Use is intended for the Healthcare Provider. Treatment with ADZYNMA should be prescribed and administered by a healthcare professional experienced in the treatment of blood disorders.

Important:

  • For intravenous injection after reconstitution only.
  • Use aseptic technique (clean and germ-free) throughout the procedure.
  • Check the expiration date of the product prior to use.
  • Do not use ADZYNMA if the expiration date has passed.

Storage of ADZYNMA

  • Store ADZYNMA at refrigeration temperature of 36°F to 46°F [2°C to 8°C] until the expiration date stated on the carton.
  • Can be stored at room temperature not to exceed 86°F/30°C for a period of 6 months, do not return to the refrigerator.
  • Do not use beyond the expiration date printed on the carton or vial or if not stored properly.
  • Do not freeze.
  • Store vials in the original package to protect from light.

Reconstitution of ADZYNMA Using the BAXJECT II Hi-Flow Needleless Transfer Device

  1. 1.

    Prepare a clean, germ-free, flat surface and gather all the materials you will need for the reconstitution and infusion. Figure A depicts the materials provided in the carton box.

    Figure A

  2. 2.

    Do not use ADZYNMA if the expiration date has passed.

    • Use ADZYNMA within 3 hours after reconstitution and keep at room temperature not to exceed 86°F/30°C. Do not store at any other temperature. Discard any unused reconstituted product if not used within 3 hours after reconstitution.
  3. 3.

    Allow the vials of ADZYNMA and diluent to reach room temperature before use.

    • If the patient needs more than one vial of ADZYNMA per injection, reconstitute each vial according to the instructions stated under “Reconstitution of ADZYNMA Using the BAXJECT II Hi-Flow Needleless Transfer Device”.
    • Inspect the reconstituted ADZYNMA solution for particulate matter and discoloration prior to administration. The solution should be clear and colorless in appearance.
    • Do not administer if particulate matter or discoloration is observed.
  4. 4. Wash and dry your hands thoroughly, and put on clean exam gloves.
  5. 5.

    Remove plastic caps from the ADZYNMA and diluent vials and place the vials on a flat surface ( Figure B ).

    Figure B

  6. 6.

    Wipe the rubber stoppers with an alcohol swab and allow them to dry prior to use. ( Figure C ).

    Figure C

  7. 7.

    Open the BAXJECT II Hi-Flow device package by peeling away the lid, without touching the inside ( Figure D ).

    • Do not remove the BAXJECT II Hi-Flow device from the package.
    • Do not touch the clear plastic spike.

      Figure D

  8. 8.

    Turn the package with the BAXJECT II Hi-Flow device upside down and place it over the top of the diluent vial. Press straight down until the clear plastic spike pierces through the diluent vial stopper ( Figure E ).

    Figure E

  9. 9.

    Grip the BAXJECT II Hi-Flow device package at its edge and pull the package off the device ( Figure F ).

    • Do not remove the blue cap from the BAXJECT II Hi-Flow device.
    • Do not touch the exposed purple plastic spike.

      Figure F

  10. 10.

    Turn the system over so that the diluent vial is now on top. Press the BAXJECT II Hi-Flow device straight down until the purple plastic spike pierces through the ADZYNMA powder vial stopper ( Figure G ). The vacuum will draw the diluent into the ADZYNMA powder vial.

    • You may notice some bubbles or foam – this is normal and should soon disappear. Wait until foam or bubbles dissipate before administration.

      Figure G

  11. 11.

    Swirl the connected vials gently and continuously until the powder is completely dissolved ( Figure H ).

    • Do not shake the vial.

      Figure H

  12. 12.

    Visually inspect the reconstituted solution for particulate matter before administration. The solution should be clear and colorless in appearance.

    • Do not use the product if particulate matter or discoloration is observed.
  13. 13.

    If the dose requires more than one vial of ADZYNMA, repeat step 1 to step 12 to reconstitute each vial.

    • Use a different BAXJECT II Hi-Flow device to reconstitute each vial of ADZYNMA and diluent.

Administration of ADZYNMA

  1. 14.

    Take off the blue cap from the BAXJECT II Hi-Flow device ( Figure I). Attach a Luer-lock syringe ( Figure J ).

    • Do not inject air into the system.

      Figure I

      Figure J

  2. 15.

    Turn the system upside down (ADZYNMA vial is now on top). Draw the reconstituted solution into the syringe by pulling the plunger back slowly ( Figure K ).

    • Use ADZYNMA within 3 hours after reconstitution and keep at room temperature (not to exceed 86°F/30°C). Do not store at any other temperature. Discard any unused reconstituted product if not used within 3 hours after reconstitution.
    • Do not administer ADZYNMA in the same tubing or container at the same time with other medicinal products for infusion.

      Figure K

  3. 16. If a patient is to receive more than one vial of ADZYNMA, the contents of multiple vials can be drawn into the same syringe. Repeat this process for all reconstituted vials of ADZYNMA until the total volume to be administered is reached.
  4. 17. Disconnect the syringe and attach a suitable injection needle or an infusion set.
  5. 18. Point the needle up and remove any air bubbles by gently tapping the syringe with your finger and slowly and carefully pushing air out of the syringe and needle.
  6. 19.

    Apply a tourniquet and clean the chosen infusion site with an alcohol swab ( Figure L ).

    Figure L

  7. 20. Insert the needle into the vein and remove the tourniquet.
  8. 21.

    Infuse the reconstituted ADZYNMA slowly, at a rate of 2 to 4 mL per minute ( Figure M ).

    • A syringe pump may be used to control the rate of administration.

      Figure M

  9. 22.

    Take the needle out of the vein, place a cotton ball or gauze on the infusion site, and apply pressure for several minutes to stop bleeding.

    • Do not recap the needle.
  10. 23.

    Place the needle, syringe, and empty vials in a puncture-resistant sharps container.

    • Do not dispose of syringes and needles in the regular waste.

Disposing of ADZYNMA

  • Vials are for single use only. Any remaining solution in the vial must not be used and must be discarded in accordance with local requirements. Dispose used vials and other supplies in an FDA cleared sharps disposal container.
  • Do not dispose of syringes and needles in the regular waste.

ADZYNMA and are trademarks of Takeda Pharmaceuticals International AG.

BAXJECT® is a registered trademark of Baxalta Incorporated.

TAKEDA® and the are registered trademarks of Takeda Pharmaceutical Company Limited.

Patented: see https://www.takeda.com/en-us/patents

Manufactured by:

Takeda Pharmaceuticals U.S.A., Inc.

Cambridge, MA 02142

U.S. License No. 1898

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

Revised: 6/2024

About this document

Source: FDA drug labeling via NLM DailyMed · Application number: BLA 125795 · View the label on DailyMed

Revision date stated in the text: June 2024

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Adzynma

Rx or OTC
Prescription (Rx)?
  • This drug is available only with a prescription from a licensed healthcare provider.
  • Rx
Boxed warning Yes – this drug has a boxed warning (also called a black box warning), the strongest warning of the FDA.
Active ingredient Apadamtase alfa
Dosage form Kit
Marketing status listed in the FDA NDC Directory
Company (applicant) TAKEDA PHARMACEUTICALS AMERICA, INC.
FDA approval BLA 125795Biologics License Application (BLA)
Manufacturers 1 labelers list this drug on DailyMed
Packages (NDC)
Package
500 IU/IU – 1 in 1 carton NDC 64764-140-05
1500 IU/IU – 1 in 1 carton NDC 64764-145-05

Source: FDA drug labeling via NLM DailyMed, data as of November 13, 2026. FDA data (DailyMed, Orange Book, Drug Shortages, enforcement reports). Not a substitute for the advice of a doctor or pharmacist.